🟢 HCWB is trading 6.2% up today as it rebounds after regaining rights to key molecules

HCWB is trading 6.2% up today at $2.06 as it rebounds from a sharp selloff on May 27, 2026, following the termination of its licensing agreement with Wugen.

• HCW Biologics regained full ex vivo rights to key immunotherapeutic molecules HCW9201 and HCW9206 after terminating its exclusive worldwide license with Wugen.
• The move is viewed as a strategic effort to increase pipeline control, despite the recent volatility in the share price.